Monday, 19 October 2026European Markets

OXURION Stock Went Up By Over 25% At Session Start On Wednesday

Loading stream...

(VIANEWS) - Shares of OXURION (BEL 20: OXUR.BR) rose by a staggering 25.71% to 0.02 € at 10:25 EST on Wednesday, after four consecutive sessions in a row of losses. BEL 20 is jumping 1.23% to 3,920.71 €, after three sequential sessions in a row of losses. This seems, as yet, an all-around bullish trend trading session today.

OXURION's last close was 0.02 €, 99.2% under its 52-week high of 1.95 €.

About OXURION

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Earnings Per Share

As for profitability, OXURION has a trailing twelve months EPS of -0.732 €.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -694.15%.

Volume

Today's last reported volume for OXURION is 11010595 which is 57.63% below its average volume of 25989200.

Moving Average

OXURION's value is above its 50-day moving average of 0.02 € and way below its 200-day moving average of 0.24 €.

Volatility

OXURION's last week, last month's, and last quarter's current intraday variation average was a negative 5.71%, a negative 2.85%, and a positive 12.84%.

OXURION's highest amplitude of average volatility was 5.71% (last week), 7.00% (last month), and 12.84% (last quarter).

Yearly Top and Bottom Value

OXURION's stock is valued at 0.02 € at 10:25 EST, way under its 52-week high of 1.95 € and way above its 52-week low of 0.01 €.

More news about OXURION (OXUR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com